Dr. Poonawalla has been felicitated with Dean’s medal for his lifelong contribution with this honor, reserved for luminaries demonstrating exceptional leadership in safeguarding, improving public health.
National, 23 May 2022 - The Johns Hopkins Bloomberg School of Public Health awarded the Dean's Medal to Serum Institute of India (SII) Chairman, Dr. Cyrus S Poonawalla for his outstanding work in developing and delivering affordable vaccines and contributing to the Indian biosciences industry for decades now. The honor was presented to Dr. Poonawalla during the Convocation ceremony held on May 21, 2022. Past award winners include social justice advocate Cheryl Dorsey, Pulitzer Prize–winning journalist Laurie Garrett and former Baltimore Health Commissioner Leana Wen.
Founding the Serum Institute of India (SII) in Pune in 1966, Dr. Cyrus Poonawalla’s foresight has helped SII achieve global leadership in terms of production with 4 billion doses annually. SII had partnered early on with UNICEF and the Pan-American Health Organization (PAHO). Its measles vaccine supply to UNICEF and PAHO between 1990 to 2016 has prevented 22 million deaths.
Gratified with this honor, Dr. Cyrus S Poonawalla, Chairman, Serum Institute of India (SII) said, “It is a proud moment for me to receive this prestigious award by Johns Hopkins Bloomberg School of Public Health. Over the years, our constant endeavor has been to provide high-quality vaccines with regular supplies, which ensure excellent immunization coverage to children and families worldwide at an affordable, sustainable price points. This award is a motivation for SII to take up bigger challenges ahead and fortifies our objective of inclusive healthcare for all.”
A biotech company, SII has been working towards the ‘right of high-quality and affordable healthcare for children’ through immunization for over six decades with governmental, intergovernmental, and non-governmental organizations on universal vaccination to reduce childhood mortality. Protecting more than two--thirds of the global infant population, SII’s vaccines has resulted in an estimated saving of 30 million lives.
Today, SII’s vaccine portfolio includes Polio vaccine, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, Rubella as well as Pneumococcal and Covid-19 vaccines. SII is credited with bringing world-class technology to India, supplying the world's cheapest vaccines to as many as 171 countries.
During the devastating pandemic, SII brought international institutes and governments together to collaborate and build innovation-driven solutions. Through strategic foresight and at-risk manufacturing, SII produced 1.9 billion doses and supplied 1.65 billion doses of COVID-19 vaccines worldwide. Fostering an R&D ecosystem of change and growth in vaccine development, SII has enabled equitable access for LMIC’s to life-saving COVID-19 vaccines, with a capacity to produce 250 million doses per month.
About SII (Serum Institute of India) Driven by the philanthropic philosophy of affordable vaccines; Serum Institute of India Pvt, Ltd. (SIIPL) is the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses), supplying the world's cheapest and WHO accredited vaccines to as many as 170 countries. It was founded in 1966 with the aim of manufacturing lifesaving immunobiological drugs including vaccines worldwide. With a strong commitment towards global health, the institute’s objective has been proliferated by bringing down the prices of newer vaccines such as such as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. SII is credited with bringing world-class technology to India, through its state-of-the-art equipped multifunctional production facility in Manjri, Pune; association with Zipline and government agencies to transform emergency medicine and critical care along with spearheading the race of vaccine development against the COVID-19 pandemic.
For more details, please contact:
Oxford R21/Matrix-M™ malaria vaccine receives WHO recommendation for use paving the way for global roll-out
Adar Poonawalla awarded 'Business Leader of the Year' 2023 by the International Advertising Association (IAA) India Chapter
Cyrus Poonawalla Group appoints Keki Mistry as Strategic Advisor to all the Financial Services Ventures led by Adar Poonawalla
R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana
Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.